The U.S. Food and Drug Administration (FDA) has approved bemotrizinol as a new active ingredient for sunscreen, marking the first such approval for a chemical UV filter in the United States in nearly 25 years. Marketed under the brand name Parsol Shield, the ingredient provides broad-spectrum protection against both UVA and UVB rays and is expected to appear in consumer products by September 2024.
Why the FDA Approval of Bemotrizinol Matters
The approval of bemotrizinol, also known as BEMT, addresses a long-standing gap in the U.S. sunscreen market. According to the FDA’s final order, the ingredient is now classified as a safe and effective UV filter for use in over-the-counter sunscreen products.
Dermatologists have long advocated for broader access to filters common in Europe and Asia, where regulations treat sunscreens as cosmetics rather than the drugs they are classified as in the U.S. The U.S. regulatory process requires rigorous safety and efficacy data, which contributed to a multi-decade delay in bringing bemotrizinol to the American market.
How Bemotrizinol Compares to Existing Filters
Current U.S. chemical sunscreens frequently rely on avobenzone to block UVA rays. While effective, avobenzone is not inherently photostable, meaning it degrades when exposed to sunlight. To compensate, manufacturers often add stabilizing ingredients, which can increase the risk of skin irritation.
In contrast, data indicates that bemotrizinol is inherently photostable. According to clinical assessments, the ingredient does not break down rapidly under UV exposure, providing consistent protection over longer periods. Furthermore, because its molecular structure is relatively large, it exhibits low systemic absorption, meaning it is less likely to penetrate the skin and enter the bloodstream compared to some older chemical filters.
Impact on Sunscreen Aesthetics and Usage
A primary barrier to daily sunscreen use is the texture and appearance of mineral-based products. Zinc oxide and titanium dioxide, the most common mineral filters in the U.S., often leave a white, chalky residue on the skin.
"Zinc is going to make you look pale, white or ashy, which really makes it hard to use on a regular basis," says Dr. Heather Rogers, a Seattle-based dermatologist. Because bemotrizinol is transparent and offers broad-spectrum protection on its own, it allows for the formulation of sunscreens that are less greasy and lack the "white cast" associated with mineral alternatives. By improving the cosmetic elegance of these products, manufacturers hope to increase consumer compliance with daily sun protection habits.
Regulatory Context and Market Availability
The path to FDA approval for bemotrizinol was both costly and lengthy. The European manufacturer DSM-Firmenich invested approximately $18 million over two decades to satisfy U.S. regulatory requirements.
Under the current FDA order, DSM-Firmenich holds exclusive marketing rights for the ingredient in the U.S. for an 18-month period. Consumers can expect to see the first wave of sunscreen products containing Parsol Shield on store shelves starting in late 2024. Despite the new technology, dermatologists emphasize that the fundamental recommendation remains unchanged: sunscreen should be reapplied every two hours, regardless of the specific filter used, to ensure continued protection against skin cancer and premature aging.
Related reading